Affiliation:
1. Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Abstract
ABSTRACT
We have found that novel pyridine oxide derivatives are inhibitors of a wide range of human immunodeficiency virus (HIV) type 1 (HIV-1) and HIV-2 strains in CEM cell cultures. Some of the compounds showed inhibitory activities against recombinant HIV-1 reverse transcriptase (RT), whereas others were totally inactive against this viral protein in vitro. Partial retention of anti-HIV-1 activity against virus strains that contain a variety of mutations characteristic of those for resistance to nonnucleoside RT inhibitors and a lack of inhibitory activity against recombinant HIV-2 RT suggested that these pyridine oxide derivatives possess a mode of antiviral action independent from HIV RT inhibition. Time-of-addition experiments revealed that these pyridine oxide derivatives interact at a postintegration step in the replication cycle of HIV. Furthermore, it was shown that these compounds are active not only in acutely HIV-1-infected cells but also in chronically HIV-infected cells. A dose-dependent inhibition of virus particle release and viral protein expression was observed upon exposure to the pyridine oxide derivatives. Finally, inhibition of HIV-1 long terminal repeat-mediated green fluorescence protein expression in quantitative transactivation bioassays indicated that the additional target of action of the pyridine oxide derivatives may be located at the level of HIV gene expression.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference19 articles.
1. Baba, M., D. Schols, R. Pauwels, H. Nakashima, and E. De Clercq. 1990. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy toward AIDS chemotherapy. J. Acquir. Immune Defic. Syndr.3:493-499.
2. Baba, M. 1997. Cellular factors as alternative targets for inhibition of HIV-1. Antivir. Res.33:141-152.
3. Balzarini, J., M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. 1992. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by a novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). J. Biol. Chem.267:11831-11838.
4. Balzarini, J., M. Stevens, G. Andrei, R. Snoeck, R. Strunk, J. B. Pierce, J. A. Lacadie, E. De Clercq, and C. Pannecouque. 2002. Pyridine oxide derivatives: structure-activity relationship for inhibition of human immunodeficiency virus and cytomegalovirus replication in cell culture. Helv. Chim. Acta85:2961-2974.
5. Barré-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science220:868-871.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献